expression Saccharomyces cerevisiae etr1D cells lacking Etr1p, the 2-trans-enoyl-thioester reductase of mitochondrial type 2 fatty acid synthase. Yeast mitochondria are used as a surrogate compartment for hosting the drug-target protein InhA from mycobacterial FASII. The heterologous enzyme is ectopically expressed in a yeast mutant strain from which the native gene encoding the corresponding mitochondrial FASII enzyme is missing. Using an appropriate fungal mitochondrial leader sequence, the mycobacterial protein is directed to the mitochondria, where it can rescue the respiratory growth phenotype of the mutant. The rationale behind the assay is that added antimycolates are foreseen to inhibit the mycobacterial enzyme, thereby recreating the respiratory deficiency of the original mutant, discernible as poor colony formation and growth on glycerol medium
gene fabV, expression of His-tagged wild-type and mutant enzymes in Escherichia coli BL21(DE3), theN-terminal His-tag in bmFabv does not have a dramatic effect on catalytic activity
into the pMALc2x vector without signal peptide coding sequence, a second construct contains in addition the sequence of the TEV protease cleaving site followed by a hexahistidine tag
the enoyl-[acyl-carrier-protein] reductase gene of Escherichia coli is cloned into a vector coding for the 6 x His tag for expression in Escherichia coli BL21DE3 cells
the enoyl-[acyl-carrier-protein] reductase gene of Plasmodium falciparum is cloned into a vector coding for the 6 x His tag for expression in Escherichia coli BL21DE3 cells
the inhA gene was cloned into the pMK1 mycobacterial expression vector under the control of the strong promoter hsp60. The resulting construct is used to transform Mycobacterium bovis BCG Pasteur in order to allow over-production of recombinant His-tagged InhA